Protein Biomarker Signatures in Precision Diagnostics of Cancer
(2023) p.487-505- Abstract
Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer. Detecting cancer, when the tumor is still localized, allows for a more efficient treatment-either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. Developing tumors consist of complex and stage-dependent genetic heterogenous cell-populations. Each cell clone can have different mutation profiles and various protein pathways activated, which often hinders single targeted therapies to embrace all the heterogenous clonalities and therefore leads to drug inefficiency, resistance, and disease relapse. Proteomics and genomics technologies have been used... (More)
Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer. Detecting cancer, when the tumor is still localized, allows for a more efficient treatment-either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. Developing tumors consist of complex and stage-dependent genetic heterogenous cell-populations. Each cell clone can have different mutation profiles and various protein pathways activated, which often hinders single targeted therapies to embrace all the heterogenous clonalities and therefore leads to drug inefficiency, resistance, and disease relapse. Proteomics and genomics technologies have been used intensively over the last two decades in the revealing of ever more clinical relevant proteins and genetic mutations and alterations. Protein-based profiling assays used for diagnostic, prognostic, predictive, and monitoring purposes are obligated to follow the country-by-country regulatory standards required by authorities with regard to medical devices.
(Less)
- author
- Winther, Henrik and Borrebaeck, Carl LU
- organization
- publishing date
- 2023-01-01
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- area under the curve (AUC), assay workflow, bioinformatics, biomarker, biopsies, cancer, China Food and Drug Administration (CFDA), circulating tumor DNA (ctDNA), clinical accuracy, cross-validation, diagnostic, enzyme-linked immunosorbent assay (ELISA), European Medicines Agency (EMA), genomics, hands-on-time (HOT), high-density antibody microarrays, immunohistochemistry, in vitro diagnostic (IVD), limit of detection, limit of quantification, mass spectrometry (MS), medical device, microarray, multiple reaction monitoring (MRM), multiplexing, next-generation sequencing (NGS), premarket approval, profiling, protein, proteomics, reaction monitoring, receiver operating characteristic, regulatory considerations, responsiveness, selected reaction monitoring (SRM), serum, specificity, turnaround time, US Food and Drug Administration (FDA)
- host publication
- Advances in Medical Imaging, Detection, and Diagnosis
- pages
- 19 pages
- publisher
- Jenny Stanford Publishing
- external identifiers
-
- scopus:85177538313
- ISBN
- 9789814877466
- 9781000602043
- DOI
- 10.1201/9781003298038-12
- language
- English
- LU publication?
- yes
- id
- 26a13906-0f60-4cb3-b691-b0a51bc35b3e
- date added to LUP
- 2024-01-09 16:15:33
- date last changed
- 2024-04-24 12:10:07
@inbook{26a13906-0f60-4cb3-b691-b0a51bc35b3e,
abstract = {{<p>Early diagnosing and patient individualized biomarker profiling are two key elements for curative interventions within cancer. Detecting cancer, when the tumor is still localized, allows for a more efficient treatment-either through surgery alone or with systemic therapies, treating a naïve and less heterogeneous tumor cell population. Developing tumors consist of complex and stage-dependent genetic heterogenous cell-populations. Each cell clone can have different mutation profiles and various protein pathways activated, which often hinders single targeted therapies to embrace all the heterogenous clonalities and therefore leads to drug inefficiency, resistance, and disease relapse. Proteomics and genomics technologies have been used intensively over the last two decades in the revealing of ever more clinical relevant proteins and genetic mutations and alterations. Protein-based profiling assays used for diagnostic, prognostic, predictive, and monitoring purposes are obligated to follow the country-by-country regulatory standards required by authorities with regard to medical devices.</p>}},
author = {{Winther, Henrik and Borrebaeck, Carl}},
booktitle = {{Advances in Medical Imaging, Detection, and Diagnosis}},
isbn = {{9789814877466}},
keywords = {{area under the curve (AUC); assay workflow; bioinformatics; biomarker; biopsies; cancer; China Food and Drug Administration (CFDA); circulating tumor DNA (ctDNA); clinical accuracy; cross-validation; diagnostic; enzyme-linked immunosorbent assay (ELISA); European Medicines Agency (EMA); genomics; hands-on-time (HOT); high-density antibody microarrays; immunohistochemistry; in vitro diagnostic (IVD); limit of detection; limit of quantification; mass spectrometry (MS); medical device; microarray; multiple reaction monitoring (MRM); multiplexing; next-generation sequencing (NGS); premarket approval; profiling; protein; proteomics; reaction monitoring; receiver operating characteristic; regulatory considerations; responsiveness; selected reaction monitoring (SRM); serum; specificity; turnaround time; US Food and Drug Administration (FDA)}},
language = {{eng}},
month = {{01}},
pages = {{487--505}},
publisher = {{Jenny Stanford Publishing}},
title = {{Protein Biomarker Signatures in Precision Diagnostics of Cancer}},
url = {{http://dx.doi.org/10.1201/9781003298038-12}},
doi = {{10.1201/9781003298038-12}},
year = {{2023}},
}